Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database

This study has been completed.
Sponsor:
Information provided by:
Taipei Medical University WanFang Hospital
ClinicalTrials.gov Identifier:
NCT01280422
First received: January 19, 2011
Last updated: NA
Last verified: January 2011
History: No changes posted
  Purpose

The doctor's overridden rate for Drug-drug interaction (DDI) alert systems was 85-95% in foreign and there was more than 90% overridden rate in Taiwan. Why DDI alerts systems which spent much time and money to establish could not use medicinal information to increase drug safety? One of the reasons which induced to override was that health care thought there were too much DDI alerts and high false alerts.

The difference between DDI alert systems from pharmacists to confirm drug-drug interaction was that pharmacists not only confirmed ordering drug at the same time but also checked the other drug information such as frequency, rote and refill etc. Therefore, DDI alert systems which were established by drug code alone would induce a lot of false alerts.

In order to study how much false alert rate in drug-drug interactions, this research selected most common drug-drug interaction which was antacids and antibiotics. Antacids were most self-payment so this research needed to analyze ROCDR (Establishing a Multi-Center, Longitudinal, Research-Oriented Clinical Data Repository for Clinical Research). The aim was to study how many drug-drug interactions and false alerts from antacids and antibiotics and analyze the difference in different department. Finally, proposing advice and assessment for building drug-drug interaction alerts system to strength drug information system and increase drug safety.


Condition
Drug Interaction Alert

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Analysis of Drug-drug Interaction Alert Based on Multicenter Clinical Database

Resource links provided by NLM:


Further study details as provided by Taipei Medical University WanFang Hospital:

Enrollment: 67128927
Study Start Date: February 2010
Study Completion Date: August 2010
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients

Criteria

Inclusion Criteria:

  • Select DDI rules: antacids and antibiotics
  • Database: ROCDR (multicenter clinical database)
  • The pharmacists defined six rules which were based on medical knowledge for true alerts or false-alert.

    1. True alert: Rule 1 and Rule 2
    2. "False-alert": Rule 3 or Rule 4
    3. "Other" (Unable to determine): Rule 5 or Rule 6

Exclusion Criteria:

  • N/A
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01280422

Locations
Taiwan
Taipei Medical University - WanFang Hospital
Taipei, Taiwan
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Investigators
Principal Investigator: Yu-Chuan Li Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Yu-Chuan Li, Department of Dermatology, WanFang Hospital
ClinicalTrials.gov Identifier: NCT01280422     History of Changes
Other Study ID Numbers: 99009
Study First Received: January 19, 2011
Last Updated: January 19, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
ROCDR

ClinicalTrials.gov processed this record on November 25, 2014